Coherus to buy Surface Oncology in stock deal valued at $65M

Kyle LaHucik

Senior Reporter

Coherus BioSciences is making a small stock-for-stock transaction to shore up its immuno-oncology pipeline in an acquisition of Surface Oncology that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Coherus to buy Surface Oncology in stock deal valued at $65M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Co­herus to buy Sur­face On­col­o­gy in stock deal val­ued at $65M

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Coherus to buy Surface Oncology in stock deal valued at $65M